MENU

Bloodlyser

The development of a pre-competitive prototype (pcp) design (bloodlyser), which can homogenize, mix and inject whole-blood, transform it into cdb and deliver the cdb to the spark olsp system.

Both the healthcare and pharmaceutical industry do a tremendous number of analyses of substances in biological fluids, of which blood is the most common. In the healthcare industry, these measurements are done to diagnose patients, determine the efficacy of administered drugs or provide for early detection of diseases. In the pharmaceutical industry, measurements are done during the development of drugs. Worldwide, billions of analyses are done each year. Blood is an extremely difficult compound to handle as it is not a fluid but a combination of liquid, cells and other components. So far, direct blood analysis has proven impossible for this project with the relevant analytical techniques. In order to measure substances in blood, the industry has chosen to create an intermediate step: create plasma from (whole-)blood. Subsequently, the substances are measured in plasma. One of the limitations of this approach is immediately obvious: we are determining concentration levels of substances in whole-blood by determining the concentration in only part of the blood. The question remains how well plasma concentrations represent whole blood concentrations - a volume correction factor is usually also required. Current sample preparation technology requires a manual transfer step to make plasma out of blood. The disadvantage is the labour involved and the fact that we are measuring from only part of the blood composition. Some substances are bound to the red blood cells and simply cannot be measured in plasma (e.g. immunosuppressant drugs). The 'Holy grail' in bio analysis (= the measurement of substances in biological fluids) would be a system that accepts whole-blood samples and delivers the result at the other end, fully automated. The advent of such a technology would enable the wide acceptance of MS technology in the healthcare market and would enhance the use of it in the pharmaceutical industry. Cell Disintegrated Blood: a breakthrough discovery The UNIVERSITY OF MUNICH has made a breakthrough discovery. When a heat shock with a specific temperature and a specific period of time is applied to blood, it transforms into a new matrix which we will call Cell Disintegrated Blood (CDB). This means the discovery of an entirely new biological matrix that will co-exist next to blood, plasma, serum and urine. CDB is a new substance with unique properties; it is a homogeneous liquid but still contains all the blood substances, unlike plasma where 45% of the material is removed. CDB can be handled like plasma without all the disadvantages of whole blood like sticking, coagulation or precipitation. Intellectual Property Rights (IPR) have been established enabling a long-term competitive advantage in the market. In the figures below, the difference between blood and CDB are obvious: all intact cellular components have disappeared. CSB is an important breakthrough for achieving the 'Holy Grail' in bio analysis. The transformation of whole-blood into CDB has already surprised scientists all over the world, when the UNIVERSITY OF MUNICH presented this concept at a congress recently, and to SPARK's opinion, is highly innovative. SPARK and the UNIVERSITY OF MUNICH have decided to research and develop a pre-competitive prototype, which can inject whole-blood automatically, after which it can be analysed by the MS. The parties involved expect the BLOODLYSER to revolutionise the blood analysis market, because automated whole-blood analysis was considered impossible. Therefore, the development of the BLOODLYSER would be a highly innovative project, especially the transformation of whole-blood into CDB. The BLOODLYSER R&D project will take approximately two years and two months. Keywords: cell, disintegrated, blood.
Acronym: 
BLOODLYSER
Project ID: 
4 112
Start date: 
01-05-2007
Project Duration: 
41months
Project costs: 
2 780 000.00€
Technological Area: 
Analytical Chemistry
Market Area: 
Diagnostic services

Raising the productivity and competitiveness of European businesses through technology. Boosting national economies on the international market, and strengthening the basis for sustainable prosperity and employment.